Literature DB >> 24019672

Solitary sternal metastasis from hepatocellular carcinoma detected by F-18 FDG PET/CT.

Koramadai Karuppusamy Kamaleshwaran1, Raghava Kashyap, Anish Bhattacharya, Bhagwant Rai Mittal.   

Abstract

Fluorine-18 fluoro-deoxy-glucose positron emission tomography (F-18 FDG PET) is not sensitive modality for the diagnosis of primary hepatocellular carcinoma (HCC). However, FDG-PET imaging may be useful in the identification of extrahepatic metastases. We report an interesting image of HCC with solitary metastasis to sternum detected by F-18 FDG PET/CT.

Entities:  

Keywords:  F-18 FDG; PET/CT; hepatocellular carcinoma; skeleton metastasis

Year:  2013        PMID: 24019672      PMCID: PMC3764688          DOI: 10.4103/0972-3919.116810

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


INTRODUCTION

Evaluation of primary hepatocellular carcinoma (HCC) using Fluorine-18 fluoro-deoxy-glucose positron emission tomography (F-18 (F-18 FDG PET) is not well-described. Extrahepatic metastases to the lung, lymph nodes, and bone are reported in up to 37% of HCC patients.[123] There is limited data on the role of F-18 FDG PET in the detection of metastasis from HCC. However, FDG-PET imaging has been reported to be an adjunct diagnostic modality in the identification of extrahepatic metastases from HCC, with a sensitivity of approximately 85%.[456] We report an interesting image of HCC with solitary metastasis to sternum detected by F-18 FDG PET/CT.

CASE REPORT

A 65-year-old male presented with pain abdomen, progressive deepening jaundice, weight loss of 15 kg and anorexia over last 6 months. Hepatitis B surface antigen was negative. Computed tomography (CT) scan of the abdomen in arterial phase showed a heterogeneously enhancing hypodense lesion in the left lobes and segment VIII of the right lobe of liver. Fine needle aspiration cytology (FNAC) was consistent with primary HCC. F-18 FDG PET/CT performed for visualizing the extent of tumor and metastatic work-up showed solitary sternal metastasis [Figure 1]. He was started on chemotherapy but later on died due to progression of the disease.
Figure 1

F-18 fluorodeoxyglucose positron emission tomography images (a) maximum intensity projection shows increased tracer uptake in the primary hepatocellular carcinoma (arrow) and also in the manubrium sternum (curved arrow). Sagittal images (b) computed tomography, (c) positron emission tomography, (d) PET/CT images show FDG uptake in the osteolytic lesion with soft tissue mass in the manubrium sterni with no other abnormal uptake elsewhere in the body. Transaxial PET/CT image (e) of the abdomen shows focal FDG accumulation (arrow) in the periphery of the hypodense lesion, a primary tumour in the liver

F-18 fluorodeoxyglucose positron emission tomography images (a) maximum intensity projection shows increased tracer uptake in the primary hepatocellular carcinoma (arrow) and also in the manubrium sternum (curved arrow). Sagittal images (b) computed tomography, (c) positron emission tomography, (d) PET/CT images show FDG uptake in the osteolytic lesion with soft tissue mass in the manubrium sterni with no other abnormal uptake elsewhere in the body. Transaxial PET/CT image (e) of the abdomen shows focal FDG accumulation (arrow) in the periphery of the hypodense lesion, a primary tumour in the liver

DISCUSSION

The prognosis of patients with HCC is related to tumor stage at presentation and underlying liver function. Reliable staging of HCC is a fundamental precondition for deciding on the treatment modality and the Barcelona clinic liver cancer staging system links tumor stage with treatment modality.[7] In particular, accurate characterization of primary and metastatic HCC, showing the tendency toward early vascular invasion of the tumor is critical for proper treatment.[8] Imaging studies by dynamic CT and contrast-enhanced MRI are important in the diagnosis and staging of HCC,[7910] but there is no consensus on which imaging tests are proper for detecting extrahepatic metastases. F-18 FDG PET/CT might be useful in the evaluation of extrahepatic metastases.[456] Kawaoka et al.[4] compared the efficacy of PET/CT, multi-detector helical computed tomography (MDCT) and bone scintigraphy for the detection of extrahepatic metastases in patients with HCC. The mean sensitivity and specificity for diagnosis of lung metastasis from HCC were 85.2% and 88.9% for MDCT, and 59.2% and 92.6% for PET-CT, respectively. For lymph node metastases, these values were 62.5% and 79.2% for MDCT, and 66.7% and 91.7% for PET-CT, respectively; and for bone metastases 41.6% and 94.5% for MDCT, 83.3 and 86.1% for PET-CT. Because, whole-body combined PET/CT using F-18 FDG effectively detects numerous cancerous lesions this method is expected to improve the accuracy of HCC staging.[11] However, the high-level of glucose-6-phosphatase in liver tissue leads to the release of FDG-6-phosphate, resulting in reduced accumulation in differentiated HCCs.[12] This case highlights the usefulness of FDG PET/CT in detecting the solitary skeletal metastasis in HCC.
  12 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  [A case of solitary sternal metastasis from unknown primary hepatocellular carcinoma].

Authors:  K Horita; Y Okazaki; A Haraguchi; M Natsuaki; T Itoh
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1996-07

3.  Increased incidence of bone metastases in hepatocellular carcinoma.

Authors:  M Fukutomi; M Yokota; H Chuman; H Harada; Y Zaitsu; A Funakoshi; H Wakasugi; H Iguchi
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 2.566

4.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.

Authors:  M A Khan; C S Combs; E M Brunt; V J Lowe; M K Wolverson; H Solomon; B T Collins; A M Di Bisceglie
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

5.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

6.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.

Authors:  Chi-Lai Ho; Simon C H Yu; David W C Yeung
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

7.  FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma.

Authors:  Tomokazu Kawaoka; Hiroshi Aikata; Shintaro Takaki; Kiminori Uka; Takahiro Azakami; Hiromi Saneto; Soo Cheol Jeong; Yoshiiku Kawakami; Shoichi Takahashi; Naoyuki Toyota; Katsuhide Ito; Yutaka Hirokawa; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2009-02       Impact factor: 4.288

8.  Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area.

Authors:  Joong-Won Park; Min An; Joon Il Choi; Young Il Kim; Seong Hoon Kim; Woo Jin Lee; Sang Jae Park; Eun Kyung Hong; Chang-Min Kim
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-22       Impact factor: 4.553

9.  Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.

Authors:  Chi-lai Ho; Sirong Chen; David W C Yeung; Thomas K C Cheng
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

10.  18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma.

Authors:  Masahiro Sugiyama; Harumi Sakahara; Tatsuo Torizuka; Toshihiko Kanno; Fumitoshi Nakamura; Masami Futatsubashi; Satoshi Nakamura
Journal:  J Gastroenterol       Date:  2004-10       Impact factor: 7.527

View more
  2 in total

1.  Extrahepatic metastasis of hepatocellular carcinoma arising from a hepatic adenoma without concurrent intrahepatic recurrence.

Authors:  N Poddar; R Ramlal; S Ravulapati; S M Devlin; S Gadani; C I Vidal; D Cao; A S Befeler; J Lai
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

Review 2.  Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.

Authors:  Run-Ze Shang; Shi-Bin Qu; De-Sheng Wang
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.